Skip to main content
. 2015 Oct 6;5:14694. doi: 10.1038/srep14694

Figure 6. A pure compound was isolated from the Chapel SA-3 isolate’s extract that inhibited the FREP1-iRBC lysate interaction and P. falciparum infection in mosquitoes.

Figure 6

(a) A bioactive pure compound showed a single peak in HPLC profile (PDA detection 190–400nm). (b) The candidate compound showed greater inhibition of FREP1 binding to iRBC lysate as the compound concentration increased. (c) The candidate pure compound (8 μg/mL) significantly inhibited P. falciparum infection. (d) The candidate pure compound’s inhibition of P. falciparum infection in mosquitoes displayed a dose-dependent pattern. N: the number of mosquitoes for each treatment; μ: the average number of oocysts per midgut; PR: infection prevalence in mosquitoes.